These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26462931)

  • 1. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy.
    Suer E; Hamidi N; Gokce MI; Gulpinar O; Turkolmez K; Beduk Y; Baltaci S
    World J Urol; 2016 Jun; 34(6):847-51. PubMed ID: 26462931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer.
    Li Z; Li Y; Lu Q; Chen J
    ANZ J Surg; 2018 Oct; 88(10):1033-1036. PubMed ID: 29974604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radical cystectomy in the treatment of bladder cancer always in due time?].
    May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
    Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.
    Herr HW
    J Clin Oncol; 2001 Jan; 19(1):89-93. PubMed ID: 11134199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.
    Kamiya N; Suzuki H; Suyama T; Kobayashi M; Fukasawa S; Sekita N; Mikami K; Nihei N; Naya Y; Ichikawa T
    Int J Clin Oncol; 2017 Apr; 22(2):353-358. PubMed ID: 27744487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
    J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.
    Eroglu A; Ekin RG; Koc G; Divrik RT
    Int J Clin Oncol; 2020 Apr; 25(4):698-704. PubMed ID: 31760524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining DWI radiomics features with transurethral resection promotes the differentiation between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer.
    Xu S; Yao Q; Liu G; Jin D; Chen H; Xu J; Li Z; Wu G
    Eur Radiol; 2020 Mar; 30(3):1804-1812. PubMed ID: 31773297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
    Sauer R; Birkenhake S; Kühn R; Wittekind C; Schrott KM; Martus P
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):121-7. PubMed ID: 9422567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer.
    Montanari E; de la Rosette J; Longo F; Del Nero A; Laguna P
    Arch Ital Urol Androl; 2012 Dec; 84(4):179-83. PubMed ID: 23427740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.